Seeking Alpha

G. Hudson's  Instablog

G. Hudson
Send Message
I am President of Sporting Advantage Inc. which markets a revolutionary basketball product I invented, now called the SKLZ RAPID FIRE basketball return system, and owner of Hudson and Affiliates which markets cost reduction services of my affiliates to medium size organizations with a hundred to... More
My company:
Save 15% OFF all SKLZ brand of sports training equipment
My blog:
GHudson Blog
View G. Hudson's Instablogs on:
  • Don't Be Surprised If SIGA Has A Major Deal Lined Up!

    After listening to SIGA's (NASDAQ:SIGA) 3rd quarter conference call, I couldn't help but think that SIGA's management either has a buyer or a major partner already lined up to help them grow their business. In this article I have referenced several quotes derived from Seeking Alpha's transcript of SIGA's call. It seemed like SIGA's management is enthusiastic about a new direction they are taking but they weren't able to disclose the details of that opportunity.

    Several of the questions from analysts on the call were sidestepped by SIGA's management but seem to indicate that those analysts also thought there was going to be a major development in SIGA's near future. Joaquin Philip Horton from Stern, Agee tried to get management to be more transparent about their intentions when he asked the following question-

    "So getting back to dengue, I know you have somebody from -- on the board from Pfizer. Has he been a lot of help in looking for a partner?"

    Obviously he, like everyone else on the call seemed to think that something was up and that it could be a major deal with Pfizer since Jeff Kindler, a former CEO of Pfizer, is currently on SIGA's board. However, management chose to try to deflect the importance of Kindler's Pfizer relationship with Eric A. Rose, Executive Chairman and CEO of SIGA's response-

    "I think to outline the specific activities of our board members is not a direction that we want to take on our conference calls. All of our directors, I think, are helpful to us across the spectrum of our activities, and that includes certainly Jeff Kindler as well."

    So that this subject was not totally avoided, another analyst that was listed as an Unknown Analyst, sometimes referred to as Fred in the transcript, followed up and tried to drill down the answer to that line of questioning-

    "so this is an interesting development in the dengue. There aren't too many partners out there, as you know and as I know. But do you do this speculatively? Let's do this and look for a partner, of which there may be a handful? Or is your research and communications and -- whatever you want to call it, which we just talked about Jeff Kindler about all this, set you on a path to this decision? It seemed like you wouldn't make this decision without knowing what the outcome was going to be?"

    Daniel Luckshire, SIGA's CFO tried to field this question with this vague answer-

    "Let's say that this decision is within the context of a broader encompassing process. This process affects the whole company. It is done with the eye toward positioning the company for growth going forward and really looking at the opportunities that are most attractive and making sure that we're positioned for these opportunities and that -- and the assets we currently have, we're managing them efficiently. Within that context, the decision was made to look for a partner for dengue and other programs with the idea that, that would be the most -- or the best path going forward to getting..."

    This line of questioning continued with the following exchanges-

    Unknown Analyst- "Well, I think the question is, to put it in a simple question, you have -- you know there's a partner for you? I mean, this is a..."

    Eric A. Rose- "Fred [ph], we can't speak to specific partnerships. So..."

    Unknown Analyst- "No, I'm not talking about specific partnerships."

    Eric A. Rose- "No."

    Unknown Analyst- "You guys, you gentlemen made this move, this kind of move that's very calculated and very important. But it can't be just half thought out. You have to have it be full thought out. So that's why I'm asking is it..."

    Eric A. Rose- "I think this is a part of the strategy that we think will propel SIGA to deliver the value that its shareholders deserve. We have a..."

    Unknown Analyst- "So this is what the company is doing. And so..."

    Eric A. Rose- "We shall say, product in -- that we've developed in smallpox. We have some earlier stage assets with regard to antiviral drug discovery that we think are partnerable. And we believe that a company with our existing assets now is in a very strong position to pursue multiple opportunities."

    Unknown Analyst- "Okay, this is not different than other, let's call, higher -- high-tech or biotech, or whatever you want to call it, research companies do, end up with partners. You would -- if you were successful in dengue, you'd have to find a partner to market it, we know that, or you will never market it yourself. So it just was a little surprising to us, at least to me, that it was just done now. Maybe it's because you're coming to year end or maybe someone was knocking on your door with a deal."

    Eric A. Rose- "We're -- we can't comment on that."

    Unknown Analyst- "So that leaves us thinking that you're smart guys and you know what to do, and there's not a -- this is a room, this is not a big dance hall, as they say. We're all wondering what the other opportunities are. You're not saying..."

    Eric A. Rose- "We can't be more specific about that at this point, Fred [ph]."

    Unknown Analyst- "Why is that? Why is that? And I don't know if I'm being unfair in asking a question, but it would seem that if you're doing all these things, you've already thought all these things out. So I was wondering why you couldn't be generally specific. Is there such a word?"

    Eric A. Rose- "Sure."

    Joaquin Philip Horton- "I'm just trying to understand what you have in mind."

    Daniel J. Luckshire- "Well, yes, to, in your words, to be generally specific, it's -- we're interested in growth opportunities that are going to create near-term value creation, whether that's through cash inflows or just a -- the point of which the value is transparent to all. So those are the types of things that we are interested in"

    All of these exchanges along with the fact that SIGA's management disclosed during the call, as documented by the below excerpt from the call transcript, that they were in the process of making changes that would reduce staff and make their overall operations more efficient lead me to believe that a major transaction is imminent-

    "At the heart of the optimization program is a commitment to match the company's resources, staff and efforts with near- and long-term opportunities. One element of the optimization program will be a reduction in the workforce. Other elements of the program include the discontinuation of our early-stage drug discovery operations and our decision to seek a partner or partners for the further development of our dengue lead candidate and other preclinical antiviral candidates. We believe such decisions are warranted in order to support efficiently the Arestvyr business and to provide the necessary financial strength and strategic focus to pursue the best growth prospects.

    Going forward, we're targeting approximately $6 million in annual cost savings from the optimization program. We expect to implement most of the changes by the end of this year. We expect to layer on the remaining changes during 2014"

    In his prepared remarks, Eric Rose also disclosed that SIGA has made significant progress on their contract with the US government and expected to complete all currently contracted shipments within the next year-

    "With the receipt of payments for delivery of product, SIGA had $105 million of cash, cash equivalents and investments as of September 30. And going forward, we plan to deliver more than 1 million additional courses within the next year, of which approximately 975,000 courses will be invoiced for the government, and the remaining courses will be free of charge."

    SIGA ended their prepared conference call remarks, with the following statement by Eric Rose-.

    "You can tell from our comments we believe this is, and continues to be, a period of value-creating transformation for our company. As evidenced by the cash received to date, the Arestvyr business is bearing fruit. And as a result of our Arestvyr business, our financial position has never been better. Lastly, and importantly, we are laying the groundwork for the next phase of innovation and growth at SIGA."

    I know some of you are thinking that all of this may be true but SIGA still has that lawsuit by PharmAthene (NYSEMKT:PIP) hanging over its head. However, anyone who has read any of my prior Seeking Alpha articles on that lawsuit- "PharmAthene's Damage Award Will Be Limited To Reliance Damages"; "PharmAthene Vs. Siga: An Open Letter To Delaware's Vice Chancellor Parsons" and "SIGA Or Pharmathene: Who Really Won?" knows that I don't think the final award will materially affect SIGA's future.

    In a hearing at his Delaware Chancery Courtroom on August 15, 2013, from this excerpt of that transcript obtained from the court reporter, Judge Parsons allowed both PharmAthene and SIGA to introduce new evidence into the case without committing as to whether he would be able to use it in determining his final ruling-

    "For all of it, the bedrock is the evidence that we have from the trial, and I am figuring that that's probably 95 percent of what I have to work with. And then as to all this new evidence, I am going to have to decide, number one, does it come in at all, is it relevant, and does it meet the requirements."

    Judge Parsons also prodded the attorneys from both PharmAthene and SIGA at that hearing to move this case along to a final conclusion before the end of 2013 as documented by this excerpt from that hearing-

    "I definitely want this hearing to happen before the end of the year, and I hope significantly before the end of the year."

    An additional valuable piece of information I learned from Mr. Crane, PharmAthene's attorney, at that hearing is that SIGA could potentially get an additional $100 Million dollars of pure profit if Arestvyr is approved as is by the FDA-

    "An additional $600 per course is reserved dependent upon FDA approval. If FDA approves -- it totals another hundred million, if they have to replace-- they don't have to refund the $300 million, Your Honor. They get the additional $100 million to produce the replacement drug. If they don't have to reproduce or replace the drug, the hundred million is all profit."

    If you take the time to listen to SIGA's entire Q3 earnings call, I think most people will conclude that something really good is about to happen. I won't be surprised if that transaction has something to do with Pfizer. With over a hundred million dollars in its coffers currently, hundreds of millions more still expected from its BARDA agreement as well as a potential major new drug, expect SIGA's stock to take a giant leap upward in the near future when a major deal is announced. I would warn people about being short SIGA as I think it's very possible that SIGA's stock price could easily double at any time especially since the October 15th 2013 short interest listed 5,970,817 SIGA shares as being shorted which equaled almost 23 days of share volume to cover.

    SIGA's share price could even reach its previous all time high of $15.66 per share in the near future. Since SIGA only has 53 million shares outstanding, a $15 per share buyout would require an investment of less than $800 million in capital. I think that's a bargain price for a biotech company with as much potential as SIGA. In Francisco Javier Garcia's July 5, 2013 Seeking Alpha article- "How The BARDA Government Contract Will Impact SIGA's Share Value", he determined a target share price for SIGA of $12.96 as follows-

    "Once the effect of incomes from the viral sales ($200 million) work their way through into the company's net asset worth, the company should have a value of $225 million, and the theoretical share price should be $4.32, in terms of the accountancy. However, the market value has to reflect the growth potential, and as in the bio-technological sector market share prices are about three times this value, this gives us an idea that the target price of the SIGA shares should be around $12.96."

    Garcia's article was actually written before SIGA's August 1, 2013 news release- "SIGA Selects Lead Candidate for Dengue Antiviral Program" which has the potential to become a huge winner for SIGA per this excerpt of Eric A. Rose's comments from that news release-

    "Tens of millions of people around the world contract some form of dengue fever each year, and the geographic reach of the disease appears to be expanding. Even the United States is not immune, with cases documented in three states over the last decade. Ultimately, we believe our work could benefit millions of people, including those living in regions where dengue is endemic, travelers to those regions, and commercial or military personnel deployed in those areas. The recent outbreaks of dengue fever in Africa and Asia underscore the need for an effective antiviral to treat this debilitating disease."

    Any way you analyze it, with the potential opportunities that lie ahead for SIGA, regardless of the outcome of the lawsuit by PharmAthene, Friday's closing share price of $3.44 seriously undervalues a company that has a very bright future ahead.

    Disclosure: I am long SIGA. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

    Tags: PIP, SIGA, long-ideas
    Nov 12 1:14 PM | Link | 1 Comment
  • Prediction: SIGA Technologies Will Win Appeal Of Pharmathene Law Suit

    On January 10th 2013 the Delaware Supreme Court listened to oral arguments regarding SIGA's appeal of the material judgment awarded Pharmathene on September 22, 2011. Delaware's Supreme Court usually decides almost all of the cases before them within 90 days but still hasn't released their final ruling concerning SIGA's appeal of this case. After researching this case in detail, I believe as does Jeff Leff, a SIGA investor, that if there is any award to Pharmathene after this appeal, it will be significantly less than the original award. Here is an excerpt of comments made by Leff on Andrew Tobias's website-

    "Jim Leff: "A friend who's also a SIGA investor tells me that an investment analysis firm hired a distinguished Delaware judge to look over SIGA's supreme court appeal and to share his findings for their big-wig investors. The judge agrees that the lower court decision (which "split the baby," awarding the plaintiff half the future revenue from SIGA's smallpox drug) was overreaching. He's confident that SIGA will be on the hook for a much, much, much lower amount (that's been my expectation, as well).""

    So that you understand the impact of that lawsuit and judgment, during the first part of 2011 SIGA's stock was trading in the $10 to $15 plus range in anticipation of future revenues including a major contract with the US government for their ST-246 drug, now being branded as Arestvyr™. From the below stock chart you can see that 2011 law suit and judgment had a dramatic effect on SIGA's stock price so that anyone should be able to understand that any adjustment of that original judgment will probably dramatically increase the value of SIGA's stock.

    (click to enlarge)

    So that you have a better understanding of the history of this lawsuit on January 3rd 2011 Pharmathene (NYSEMKT:PIP) commenced a breach of contract action against SIGA Technologies (NASDAQ:SIGA) (referred to as SIGA herein) per this Jan. 24, 2011 PR Newswire including the following excerpt-

    "In December 2006, the Company filed a complaint against Siga in the Delaware Court of Chancery, alleging, among other things, that the Company has the right to license exclusively development and marketing rights for Siga's drug candidate, ST-246, pursuant to a merger agreement between the parties that was terminated in October 2006. The complaint also alleges that Siga failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement. Siga has counter sued claiming that PharmAthene breached its duty to engage in good faith negotiations for a license to ST-246 during the fall of 2006."

    Also here is an excerpt fromSIGA's website explaining their new product Arestvyr™

    "Our lead product candidate, Arestvyr* (USAN tecovirimat; aka ST-246®) is a drug under development for the treatment of smallpox - one of the deadliest diseases that mankind has ever faced and a formidable bioterrorism and biowarfare threat.

    SIGA has entered into a contract, in excess of $400 million, with the Biomedical Advanced Research and Development Authority (BARDA) for the delivery of 2 million courses of Arestvyr to the Strategic National Stockpile.

    *Arestvyr is an investigational product that is not currently commercially available in the United States. It has not been determined by the U.S. Food and Drug Administration to be safe and effective for the treatment of smallpox or any other indication."

    As the trial progressed, SIGA's share price dropped dramatically, as documented by the above chart, to as low as $1.78 on December 5th 2011 after a significant judgment was awarded to Pharmathene on September 22, 2011. A Final Order and Judgment was handed down by the Delaware Chancery Court which dramatically awarded a significant portion of SIGA's potential profits from their lead product Arestvyr* as per this excerpt from that ruling (link to Pharmathene's website for rulings)-

    "PharmAthene is granted an equitable remedy in the form of an

    "equitable payment stream" to the extent set forth in and in accordance with the other terms and conditions of this Final Order and Judgment, as follows:

    a. Once SIGA earns $40 million in Net Profits,1 PharmAthene shall be paid fifty percent (50%) of all Net Profits for a period from entry of this Final Order and Judgment until expiration of ten (10) years following the "First Commercial Sale" (the "Payment Period") as determined in accordance with this Final Order and Judgment, unless the Payment Period is terminated earlier as set forth below under Paragraph 2(e)."

    Also a large award for attorneys' fees was awarded to PharmAthene as a result of their Judgment victory as per this excerpt from that same Final Order and Judgment-

    "PharmAthene is awarded certain fees, expenses, and costs as follows and to the extent set forth and supported pursuant to Court of Chancery Rule 88: (NYSE:A) one-third of "its reasonable attorneys' fees and expenses up to the date of the Opinion totaling $1,854,079.43; (NYSE:B) 100% of its is reasonable attorneys' fees and expenses from the date of the Opinion through the date of this Final Order and Judgment totaling $154,482.58;

    (NYSE:C) one-third of its expert witness costs totaling $402,148.31; and (NYSE:D) post-Judgment interest on all of the amounts identified in this Paragraph 3, which collectively total $2,410,710.32, at the legal rate (5% plus the current Federal Reserve Discount Rate of 0.75% and as adjusted with future changes in the Federal Reserve Discount Rate, if any) from the date of this Final Order and Judgment until the award of such fees, expenses, and costs is satisfied."

    At the center of this disagreement between SIGA and Pharmathene is the enforceability of an agreement referenced as their LATS (License Agreement Term Sheet). Even though the Chancery Court Judge specifically ruled there was no binding contract as a result of the LATS per this excerpt from the September 22, 2011 opinion,-

    "The LATS was not a binding license agreement"

    the Chancery Court Judge went on to find SIGA legally liable for the above Judgment as a result of the terms listed in the LATS and referenced in both the Bridge Loan Agreement and the Merger Agreement per this excerpt from that same opinion.-

    "I have found SIGA liable (1) for breach of its obligations under Section 2.3 of the Bridge Loan Agreement and Section 12.3 of the Merger Agreement to "negotiate in good faith with the intention of executing a definitive License Agreement in accordance with the terms set forth in the [LATS]" and (2) under the doctrine of promissory estoppel."

    In the January 10th oral arguments before Delaware Supreme Court which you can listen to at this link, you can listen to the judges questioning about the requirement to negotiate in good faith. Here is recap of some key points one of the Judges hearing this appeal made-

    "Isn't there a heads I win, tails you lose aspect to a claim for a breach of the duty to negotiate in good faith and by that I mean if any relief at all is granted whether it's reliance damages or expectation damages that necessarily presupposes that the negotiations would have concluded with some agreement and that speculative by its very nature because that's unknowable- So that's the heads I win - the tails you lose is that if full effect is given to that argument then no relief is granted and which case why recognize a claim for breach of the duty to negotiate in good faith at all and yet we have that?"

    "Isn't there some states that don't recognize a duty to negotiate in good faith as a practical term?

    Here is an excerpt from an article by Herbert Smith Freehills LLP titled- "Developments In Agreements To Negotiate In Good Faith"-

    "In the absence of a binding English authority to the contrary, the starting assumption for parties contracting under English law will remain that obligations to negotiate in good faith are likely to be considered unenforceable, regardless of whether they are express or implied."

    It would seem obvious that Pharmathene would not have sued SIGA for the enforcement of the LATS, which included terms requiring Pharmathene to provide several million dollars of upfront capital, if SIGA's Arestvyr™ had failed some of its tests and/or for whatever reason, didn't appear to be on its way to becoming a successful product. So from that aspect, why is it any different for SIGA to change its position while negotiating the final LATS?

    Another main area of concern debated during SIGA's appeal was the reasonableness of the Delaware Court of Chancery awarding such a large judgment to Pharmathene based upon the earnings over the next 10 years from SIGA's unproven drug as being expectation damages. Here is an excerpt about expectation damages from the National Paralegal College-

    "Expectation damages can only be recovered if they can be calculated to a reasonable certainty. Where damages cannot be calculated to a reasonable certainty, the injured party will only be able to recover nominal damages. (We will discuss nominal damages a little bit later).

    Typically, the issue of certainty arises in cases where the damages suffered are in the form of lost profits. The general rule regarding lost profits and certainty in calculating damages is that if the injured party is an established business, lost profits are not treated as speculative because they can be estimated from past profits. Therefore, an established business will generally recover for its lost profits.

    However, where the injured party is a new business so that there are no past profits with which to estimate future profits, the courts examine each case individually and, if the courts can calculate damages to a reasonable certainty, then damages will be awarded. However, in the event that courts cannot, the injured party will be awarded nominal damages only."

    Since the future success of SIGA's drug, especially as of the time of Pharmathene's involvement, was highly speculative, it would seem obvious that Pharmathene should not have been entitled to speculative damages and at most might be entitled to nominal damages or reliance damages.

    On the positive side for shareholders of SIGA, on top of what I believe will be a positive outcome from their appeal, they have already begun shipping courses of Arestvyr™ per this article- "SIGA Delivers First Courses of Arestvyr™ Under BARDA Contract" - NEW YORK, March 12, 2013 (GLOBE NEWSWIRE)-

    "SIGA may begin to obtain payment under the BARDA contract once it has delivered 500,000 of the 2,000,000 contracted-for courses of Arestvyr. This first delivery of approximately 190,000 courses moves SIGA much closer to that moment."

    Since the initial conversations between SIGA and the United States government involved a lot more courses than the current 2 million contracted amount, I believe there is a high chance of many more courses of their drug being ordered by our government. Also with this world facing even more fear from all of the terrorists and their various tactics, the worldwide demand for Arestvyr™ could be much greater than originally anticipated. On top of increased demand for Arestvyr™ , as of 3/15/2013 SIGA has a large short interest of 7,527,209 shares which equals almost 17 days of SIGA share volume to cover.

    In reviewing SIGA's 2012 Annual Report, I couldn't help notice they made an adjustment to their Deferred tax assets to increase the current portion to $33,515,327 and the long term portion to $10,209,278. The current portion of this asset would indicate to me that they expect to use carryforward losses enough to offset $95,758,077 ($33,515,327 divided by 35%(estimated tax rate)) of taxable income in 2013. This would indicate the company expects a net profit of $62,242,750 ($95,758,077 - $33,515,327). This would be equivalent to approximately $1.20 EPS ($62,242,750 divided by 51.6 million shares) for 2013.

    Even if SIGA loses its current appeal of the Pharmathene judgment, I believe its share price is worth more than the current share price of $3.45 but if they win their appeal, it wouldn't surprise me for SIGA's share price to quickly jump to somewhere between $10 and $15.

    Disclosure: I am long SIGA. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

    Apr 10 6:44 AM | Link | 7 Comments
  • Herbalife Has A Short Problem Not A Business Model Problem

    While Herbalife's (NYSE:HLF) short interest increased by 3,747,253 over the period 11/15/12 through 11/30/12, Herbalife's closing share price as of 11/30/12 was only 36 cents lower than at 11/15/12.

    Settlement Date

    Short Interest

    Closing Share Price


    In Short Interest*


    In Closing Share Price*




    $ (0.36)





    $ (5.38)





    $ (0.89)





    $ 4.84





    $ (5.13)





    $ 4.14







    *- Increase/(Decrease) calculated from prior Settlement Date listed

    Since David Einhorn's infamous questions on Herbalife's May 1st conference call, shorts want investors to believe the reason Herbalife's share price has stayed below $50 for a good portion of the last 7 months is that Herbalife has some major underlying problems. However from the above chart you can see that since 8/31/12 shorts have added 8,244,135 (20,724,933 - 12,480,858) shorted shares to their positions and were only able to drive down HLF's share price ($48.39 - $45.61) $2.78 over that time period. This equals driving down the share price only one cent per 29,655 of shares shorted. So this leads me to believe that the recent share price movement has been affected more by shorts driving the share price lower than any actual problems inside the company.

    This recent dramatic increase in short interest has not been as a result of any new information coming to light about Herbalife. In fact, the only real information that has been derived from Einhorn, who was used as one of the main reasons for this short attack, since May 1st, is summarized below by This information refers to his presentation at the Value Investing Congress on October 2, 2012 -

    "Einhorn also mentions Herbalife , talks about him asking questions on the conference call. Because he said people were worried about the quarter. Says he was quite surprised by the reaction.

    "Do your homework and kick the tires." It's not the answers that make you good in this business, it's the questions you ask. So He mocks investors for not doing the work, but just trying to blindly follow him. DO YOUR OWN WORK!"

    As though it's not enough for Einhorn to be surprised as to the market's reaction, I have researched and written articles for Seeking Alpha that have countered every single point which has been presented by all of the other critics of Herbalife. The shorts main accusation of Herbalife being a pyramid has been brought up many times over the years including during the last short attack on Herbalife back in 2008/2009 without any actual ramifications to the company. I believe my two Seeking Alpha articles- "Herbalife Information Disputes Pyramid Allegations" and "Herbalife's Nutritional Club Sales Will Take Company To The Next Level" present an easy to understand documentation of why investors in Herbalife don't have to worry about this claim by the shorts.

    All other argumentsbrought forward by those critics of Herbalife have not had any effect on the company and must not worry Herbalife's COO Richard Goudis as he just added $3.1 million in Herbalife shares to his position. With a healthy dividend now yielding 2.6% and potentially growing, it would seem Herbalife longs don't have a lot to worry about.


    However I believe that Friday's (January 14th) stock action is a precursor to the shorts attempt at driving down Herbalife's shares down below $40 before this Friday's option expiration date. My fellow Seeking Alpha author Richard Pearson asserts in his article- "The Surprising Truth Behind Herbalife Put Volume" that the large ("whale") short positions have been selling large put positions in Herbalife-

    "A fairly simple technical analysis of what has been going on with the stock and the puts shows that, whoever he is the "whale" is almost certainly SELLING puts against a short position in the stock serving as a hedge. By doing this, the whale is collecting millions of dollars in option premiums direct from the pockets of smaller speculators, while taking on virtually no risk."

    I agree with Mr. Pearson's assertion that the large put action we have seen in Herbalife is probably from the whale selling puts. However I believe he may have an additional use for having sold those puts than just a hedge. First lets look at the volume of open interest in December 22, 2012 put options-

    Put Option Strike PriceOpen Interest as of 12/14/2012

    Before discussing my thoughts as to the whale's intentions, here is another excerpt from Mr. Pearson's article-

    "the economics of buying puts is inferior to shorting common stock unless the buyer buys them close to expiration and has a clear view on timing of a share price move"

    I agree with the author that there is generally more profit to be made by shorting a stock when you believe it will go down than buying put options. So if we are to believe as Mr. Pearson believes that there is a major short "whale" who owns a large portion of the almost 21 million shares shorted of Herbalife and who also has sold a large percentage of the December 22, 2012 puts, we can only speculate as to what his attentions are.

    Obviously if there isn't any real underlying problem with Herbalife's business, then the best outcome the whale can hope for is that a large number of longs capitulate by this Friday and sell their shares at the lowest possible share price. I believe that the whale's intentions are to continue to add to his short position this week, driving down Herbalife's share price below $40, with the intent of breaking the will of Herbalife's longs so that many longs capitulate selling the whale their shares at a low price. Also the whale will be able to use those put options that he sold to cover an additional 3 million+ shares that have been shorted.

    Even though the whale has a large amount of capital, there is still a lot of risk involved in trying to add even more shares to his short position in an attempt to drive Herbalife's share price down. I would have to believe we will be hearing some negative news about Herbalife this week while he is attempting to drive the share price down. Also I would warn anyone trying to join in shorting Herbalife at the current share price level will be taking an even greater risk than the whale since they won't have the benefit of having sold put options at significant premiums. There could be a significant move upward in the share price if Herbalife and other investors step in as well as if the whale is forced to reverse his position.

    The good news for long term Herbalife investors is that Herbalife has up to a billion dollars available to buy back shares. If Herbalife and other investors step in driving the share price back up before Friday's close, the whale could end up with a lot more short positions than he planned as well as having to deal with a rising share price. Herbalife investors need to look beyond this Friday as there are many reasons to invest as recently reported by another fellow Seeking Alpha author, Bret Jensen- "Recent Insider Buying Heads List Of Reasons To Buy Cheap Herbalife" Any way you look at this, Herbalfe longs that endure this short attack and hold on to their shares will be greatly rewarded over the next 6 to 12 months.

    Disclosure: I am long HLF.

    Additional disclosure: I wrote this article as of Friday 12/14/2012 close. Since the article was not immediately accepted by Seeking Alpha to be published as a premium article, I took steps this morning 12/17/2012 selling some shares short as well as selling some puts to protect my long position.

    Tags: HLF
    Dec 17 11:48 AM | Link | 1 Comment
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.